IT'S IMPORTANT TO KEEP UP WITH YOUR TREATMENT SCHEDULE
EYLEA is the only FDA-approved treatment for Wet AMD with a recommended dose of 2 mg administered by injection in the eye every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by injection once every 8 weeks (2 months). EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective, patients may also be treated with 1 dose every 12 weeks after 1 year of effective treatment. Patients who have this dosing schedule should have their vision checked regularly. Your eye care team will determine the EYLEA dosing schedule that's right for you.
Your eye care team will want to see you regularly to check your vision and also check your treatment progress with EYLEA. Work with your eye care team to make sure you can keep your appointments and stay on your recommended treatment schedule.
Safety information for EYLEA
EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA.
It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.